• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lowey Dannenberg Notifies ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

By: Lowey Dannenberg, P.C. via GlobeNewswire
December 12, 2023 at 12:43 PM EST

NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) for violations of the federal securities laws on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, both dates inclusive (the “Class Period”).

On November 15, 2023, a complaint was filed against the Company and certain of its former and current officers and director alleging that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) izokibep was less effective in treating HS than Defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep’s clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company’s business prospects post-IPO; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

When investors learned the truth, Acelyrin’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $50,000 in Acelyrin’s securities, and wish to participate, or learn more, please contact our attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com).

Any investor who wishes to serve as Lead Plaintiff must act before January 16, 2024.

About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: investigations@lowey.com

SOURCE: Lowey Dannenberg P.C.


Primary Logo

More News

View More
Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2
Today 16:18 EDT
Via MarketBeat
Tickers MS T TMUS VZ
Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
Today 16:10 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers GEV GOOGL NOW
Act Fast: These 3 Undervalued Stocks Won’t Stay Low for Long
Today 14:25 EDT
Via MarketBeat
Tickers ALB INTC XPEV
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
Today 14:00 EDT
Via MarketBeat
Topics Economy
Can HCA Healthcare Revive the Market’s Weakest Sector?
Today 13:42 EDT
Via MarketBeat
Topics Earnings
Tickers HCA UNH
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap